Printer Friendly

GYNEX BEGINS SHIPPING DELATESTRYL INITIATING ITS FIRST REGULAR REVENUE STREAM

 GYNEX BEGINS SHIPPING DELATESTRYL
 INITIATING ITS FIRST REGULAR REVENUE STREAM
 VERNON HILLS, Ill., June 17 /PRNewswire/ -- Gynex Pharmaceuticals, Inc. (NASDAQ: GYNX) today announced it began to ship its first approved drug providing the company with its first source of regular revenues. Gynex received the exclusive U.S. rights to the drug, Delatestryl(R), from Bristol-Myers Squibb in March 1992.
 Delatestryl (testosterone enanthate) is an injectable testosterone product currently used for treating patients with hypogonadism (testosterone deficiency), a condition associated with impotence, decreased libido, insufficient muscle development and bone loss. Approximately 400,000 American men suffer from this condition. The product is also prescribed for delayed puberty, a problem for about 80,000 American boys. Bristol-Myers Squibb continues to manufacture the product for Gynex.
 "We have begun shipments and promotion of Delatestryl to the trade and physicians," said Stephen M. Simes, president. "In addition to direct communication with 400 drug wholesalers in the United States Gynex expects to generate awareness through direct mailings to 66,000 pharmacists as well as promotion in the country's 10,000 urologists and endocrinologists. As a result of these and other marketing efforts, we hope to increase annual revenues from this product above the $2 million level traditionally experienced by Bristol-Myers Squibb."
 Gynex continues limited distribution of another drug, Oxandrin(TM), through an FDA Treatment IND (investigational new drug) and similar authorization in Canada, for delayed growth and puberty. This allows the company to begin charging for costs related to production, distribution and research while the clinical trial is conducted and during FDA review. The Phase III human clinical trial of Oxandrin(TM) in boys with delayed growth and puberty is in progress and is expected to be completed in early 1993.
 Gynex Pharmaceuticals, Inc., based in Vernon Hills, is a research- based pharmaceutical company that develops and markets products for use in endocrinology, metabolism, AIDS and gynecology.
 -0- 6/17/92
 /CONTACT: Stephen Simes, president of Gynex Pharmaceuticals, 708-913-1144, or Lynne Franklin, 312-266-7800, for Gynex Pharmaceuticals/
 (GYNX) CO: Gynex Pharmaceuticals Inc. ST: Illinois IN: MTC SU:


CK -- NY034 -- 1036 06/17/92 11:04 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 17, 1992
Words:350
Previous Article:CAPSTEAD MORTGAGE CORPORATION ANNOUNCES PROPOSED MERGER WITH TYLER CABOT MORTGAGE SECURITIES FUND, INC.
Next Article:INTERNATIONAL MOBILE MACHINES RECEIVES FIRST ORDER FROM VENEZUELA
Topics:


Related Articles
GYNEX REPORTS ADVANCE IN GROWTH DISORDER RESEARCH
GYNEX PHARMACEUTICALS REPORTS FIRST REGULAR REVENUE STREAM FOR SECOND QUARTER, SIX MONTHS
GYNEX PHARMACEUTICALS ANNOUNCES CHANGES IN BOARD OF DIRECTORS, CONTINUED OPERATIONAL ADVANCES
GYNEX BEGINS AIDS PATIENT TESTING OF POTENTIAL NEW DRUG THERAPY
GYNEX BEGINS PHASE III TRIAL OF POTENTIAL NEW TESTOSTERONE THERAPY
GYNEX RECEIVES FDA APPROVAL OF TREATMENT IND FOR USE OF OXANDRIN(TM) IN GROWTH DISORDER
GYNEX PHARMACEUTICALS ANNOUNCES FIRST ORAL DRUG FOR TURNER SYNDROME
GYNEX PHARMACEUTICALS AND BIO-TECHNOLOGY GENERAL AGREE TO MERGE
GYNEX PHARMACEUTICALS REPORTS FIRST YEAR OF REGULAR REVENUE STREAM; MERGER PLANNED WITH BIO-TECHNOLOGY GENERAL
GYNEX DRUG CUTS DEATH RATE IN ALCOHOLIC HEPATITIS STUDY; GYNEX PLANS TO INCLUDE RESULTS IN FDA SUBMISSION BY THE END OF 1993

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters